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A B S T R A C T
A series of piperazinyl-β-carboline-3-carboxamide derivatives were designed through a molecular hybridization
approach. Designed analogues were synthesized, characterized and evaluated for anti-leishmanial activity
against Leishmania infantum and Leishmania donovani. In L. infantum inhibition assay, compounds 7d, 7g and 7c
displayed potent inhibition of promastigotes (EC50 1.59, 1.47 and 3.73 µM respectively) and amastigotes (EC50
1.4, 1.9 and 2.6 µM respectively). SAR studies revealed that, para substitution of methoxy, chloro groups and
methyl group on ortho position favored anti-leishmanial activity against L. infantum. Among these analogues 7d,
7h, 7n and 7g exhibited potent inhibition against L. donovani promastigotes (EC50 0.91, 4.0, 4.57 and 5.02 µM
respectively), axenic amastigotes (EC50 0.9, 3.5, 2.2 and 3.8 µM respectively) and intracellular amastigotes (EC50
1.3, 7.8, 5.6 and 6.3 µM respectively). SAR studies suggested that, para substitution of methoxy group, para and
meta substitution of chloro groups and benzyl replacement recommended for significant anti-leishmanial against
L. donovani.
1. Introduction
Leishmaniasis is caused by intracellular protozoan Leishmania spp
parasites and is considered as one of the most neglected tropical dis-
eases. Among various clinical forms of leishmaniasis, visceral leish-
maniasis is the most severe, affecting internal organs like bone marrow,
liver and spleen. VL is also known as kala-azar and is lethal if untreated
in over 95% of cases. VL caused by Leishmania donovani and Leishmania
infantum [1,2]. Leishmaniasis control is majorly dependent upon che-
motherapy that includes decade old drugs, due to no effective vaccines.
Antimonial drugs such as sodium stibogluconate and meglumineanti-
moniate have been used for the last 70 years, however increasing in-
cidence of resistance has been reported [3]. Anti-leishmanial drugs such
as amphotericin B, diamidine, pentamidine and paromomycin has been
restricted by cost, toxicity and resistance [4,5]. Miltefosine is originally
developed as anti-cancer agent, has been approved by FDA for leish-
maniasis treatment [6]. Miltefosine has restricted use in pregnancy and
has high risk of resistance due to long half-life (150 h). Clinical efficacy
of miltefosine has been decreased in countries like India, where it is
used extensively [7]. Based upon these collective facts, there is an
increased need of new anti-leishmanial agents with good therapeutic
profiles.
Nature and natural products remain an important source for the
development of therapeutic agents. Natural products especially alka-
loids have been known for anti-infective activity. β-carboline represents
a tricyclic pyrido[3,4-b]indole ring system has reported for wide spec-
trum of biological activities. β-carboline derivatives displayed different
biological activities such as anti-microbial [8], anti-cancer [9], anti-
leishmanial [10,11], anti-malarial [12,13], anti-tubercular [14], anti-
viral [15] and anti-thrombotic activities [16]. β-carboline alkaloids
such as Harmine, annomontine and manzamines (Fig. 1) exhibited
potent anti-leishmanial activity [10,17,18]. Manzamine is a group of β-
carboline alkaloids, possess complex structure of β-carboline moiety
attached to a pentacyclic diamine ring having both eight and thirteen
membered rings on a pyrrolo[2,3-i] isoquinoline framework. Large
numbers of manzamine alkaloids are isolated from different marine
sponge species and exhibited potent anti-leishmanial activity. Beside
these natural β-carboline alkaloids, several synthetic β-carboline deri-
vatives having different substitutions on 1, 2, 3 and 9 positions have
exhibited significant anti-leishmanial activity [18,19]. Among these
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synthetic β-carboline derivatives, β-carboline derivatives with N-al-
kylcarboxamide group on 3 position displayed potent anti-leishmanial
activity and attracted us to design new β-carboline derivatives [20–23].
The piperazine moiety has privileged position in medicinal chemistry
with diverse biological activities [24]. Bisarylpiperazine derivatives
exhibited activities such as anti-leishmanial [25], anti-microbial
[24,26,27], anti-protozoal [28,29], anti-cancer [30], anti-tubercular
[30,31] and anti-viral [32] (Fig. 1). Based upon literature reports, in the
present study we designed β-carboline and piperazine hybrid molecules
(Fig. 1) using molecular hybridization approach.
2. Results and discussion
2.1. Chemistry
The synthetic scheme for β-carbolinepiperazine derivatives was
illustrated in Scheme 1. The titled compounds were synthesized using
DL-Tryptophan (1) as starting material. Initial esterification of DL-
Tryptophan (1) using thionylchloride to get an ethyl ester of tryptophan
(2), was followed by pictet-spengler reaction in presence of tri-
fluoroacetic acid to obtain tricyclic ethyl 2,3,4,9-tetrahydro-1-phenyl-
1H-pyrido[3,4-b]indole-3-carboxylate (3). Upon oxidation with po-
tassium permanganate, ethyl-1-phenyl-9H-pyrido[3,4-b]indole-3-car-
boxylate (4) was obtained, and is continued by 9-N methylation with
methyl iodide in presence of potassium hydroxide to acquire ethyl-9-
methyl-1-phenyl-9H-pyrido[3,4-b]indole-3-carboxylate (5). Further al-
kaline ester hydrolysis of compound (5) produced 9-methyl-1-phenyl-
9H-pyrido[3,4-b]indole-3-carboxylic acid (6) as key intermediate. The
carboxylic acid key intermediate (6) was treated with appropriate
amines (aryl-substitutedpiperazines) in presence of coupling agent 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI)
and hydroxybenzotriazole (HOBt) to obtain the desired products (7a-p)
Fig. 1. Structure of reported and designed β-carboline-piperazine hybrid molecules.
Scheme 1. Reagents and conditions: (i) thionylchloride, ethanol, reflux, 30min, 76%; (ii) benzaldehyde, trifluoroacetic acid, DCM, rt, 3 h, 82%; (iii) KMnO4, THF, rt,
24 h, 68%; (iv) methyliodide, KOH, DMSO, rt, 30min, 72%; (v) 50% aq. NaOH, reflux, 30min, 78%; (vi) EDCl, HOBt, THF, piperazines, 0 °C-rt 6 h, 62–82%.
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in good yields [33–35].
2.2. Biological evaluation
2.2.1. Cytotoxicity evaluation
Initially all these reported β-carboline derivatives were evaluated
for cytotoxicity against HeLa cell lines at 500 μM by an Alamar blue
assay, which showed most of these compounds were non-toxic to HeLa
cells at tested concentration. Compounds which showed cytotoxicity
against HeLa cells were further evaluated to determine cytotoxic con-
centration (CC50) value. Among these reported β-carboline derivatives,
compound 7o and 7p showed cytotoxicity (CC50 29.7 and 27.3 μM,
respectively) against HeLa cells.
2.2.2. Anti-leishmanial screening
Anti-leishmanial activity of these analogues was determined by
evaluating their inhibition activity against both promastigote, amasti-
gote forms of Leishmania infantum and Leishmania donovani strains.
Compounds were screened against promastigote forms of the
Leishmania strains to determine their effective concentration (EC50)
values. Finally, compounds which exhibited potent inhibition of pro-
mastigote (EC50 < 20 µM) were further evaluated against amastigote
forms of respective strain using established axenic and intracellular
amastigote assay methodologies. Anti-leishmanial drugs miltefosine
and pentamidine were used as standards for comparison purpose.
2.2.2.1. Leishmaniainfantum
2.2.2.1.1. Anti-promastigote activity. Anti-promastigote activity of
these reported β-carboline derivatives was determined by Alamar
blue assay method. In in-vitro evaluation against promastigotes of L.
infantum, compounds 7g, 7d, and 7c displayed potent anti-
promastigote activity (EC50 1.47, 1.59 and 3.73 µM respectively) than
standard drugs pentamidine and miltefosine (EC50 8.31 and 12.36 µM
respectively). Compounds 7a, 7f, 7j and 7k displayed significant
inhibition of L. infantum promastigotes (EC50 9.45, 13.8, 19.7 and
17.2 µM respectively) and inhibition potency was comparable with
standard drugs. Analogues 7n, 7b and 7h exhibited moderate activity
(EC50 20.4, 24.3 and 21.7 µM respectively), while 7d, 7h, 7l, 7m, 7o
and 7p showed weak anti-promastigote activity (EC50 72.4, 50.9, 64.9,
93.0, 29.7 and 45.7 µM respectively) against L. infantum. Especially,
compounds 7d and 7g exhibited most promising inhibition of L.
infantum and are five times more potent than the standard drugs.
Structure activity relationship studies suggested that, para substitution
with ortho-para directing groups (methoxy and chloro) enhanced
promastigotes inhibition activity significantly. Ortho substitution with
methyl group has increased the anti-promastigote activity significantly
while substitution of other ortho-para directing and meta directing
groups (methoxy, chloro) substitution on phenyl ring has decreased the
activity drastically. Replacement of phenyl ring with benzyl and pyridyl
ring was not favorable for anti-promastigote activity.
2.2.2.1.2. Anti-amastigote activity. Compounds exhibited significant
inhibition of L. infantum promastigotes (EC50 < 20 μM) were further
evaluated against axenic amastigote forms of L. infantum. Alamar blue
assay method was used to determine inhibition potential of these β-
carboline derivatives against (human life stage forms) axenic
amastigotes. In L. infantum axenic amastigote inhibition assay,
compounds 7d, 7g and 7c displayed potent activity (EC50 1.4, 1.9
and 2.6 µM respectively) better than standard drugs pentamidine and
miltefosine (EC50 2.7 and 4.8 µM). Compound 7a showed axenic anti-
amastigote activity (EC50 4.5 µM) against L. infantum and potency was
comparable with standard drugs. Compounds, 7j, 7k and 7f exhibited
significant inhibition of L. infantum axenic amastigotes (EC50 14.6, 15.0
and 15.3). In-vitro anti-amastigote activity results (Table 1) suggested
that these β-carboline derivatives were more potent against axenic
amastigote forms of L. infantum.
Structure Activity Relationship (SAR). Among these piperzinyl-β-
carboline derivatives, un-substituted proto compound displayed sig-
nificant anti-leishmanial activity against both promastigote and amas-
tigotes of L. infantum. A series of β-carboline derivatives with different
ortho-para and meta directing groups on various positions of phenyl
were studied to determine their effect on anti-leishmanial activity.
Substitution of ortho-para directing methyl group on ortho position of
phenyl ring has increased anti-leishmanial activity significantly against
both forms, whereas methyl substitution on para position has reduced
the activity. Ortho-para directing groups such as methoxy and chloro on
para substitution strongly enhanced the anti-leishmanial activity, while
ortho substitution lessen the activity and meta substitution drastically
decreased the activity. Meta directing nitro and fluoro group substitu-
tion on para position decreased the activity considerably and fluoro
substitution on ortho position severely decreased the activity. Dual
substitution on ortho and meta position with chloro declined the ac-
tivity. Moreover, phenyl ring replacement with pyridine and benzyl
ring has adversely affected the anti-leishmanial activity. SAR studies
suggested that, meta position of phenyl ring is highly susceptible,
substitution with any group drastically reduced the activity. Ortho-para
directing methoxy, chloro groups on para position and methyl group on
ortho position favored the activity. Phenyl ring replacement with het-
erocyclic rings is not recommended for anti-leishmanial activity against
L. infantum.
2.2.2.2. Leishmaniadonovani
2.2.2.2.1. Anti-promastigote activity. L. donovani promastigote
inhibition potency of these reported β-carboline derivatives was
determined by Alamar blue assay method. Among these analogues,
compound 7d exhibited potent inhibition (EC50 0.91 µM) of L. donovani
promastigotes than standard drugs pentamidine and miltefosine (EC50
6.4 and 3.12 µM). Anti-promastigote activity of analogues 7h, 7n and
7g (EC50 4.0, 4.57, and 5.02 µM respectively) is equipotent as that of
standard drugs. Compounds 7f, 7p, 7c, 7a, 7k, 7j, 7b, 7i, and
7odisplayedsignificant inhibition (EC50 8.42, 8.5, 9.45, 11.9, 12.4,
13.1, 14.2, 15.2 and 19.5 µM respectively) of promastigote and
inhibition potency is comparable with standard drugs. Compound 7e
showed moderate (EC50 28.5 µM) anti-promastigote activity and 7l and
7m displayed weak inhibition (EC50 85.9 and 117.5 µM) of L. donovani
promastigotes.
2.2.2.2.2. Axenic amastigote screening. Compounds exhibited
significant anti-promastigote activity (EC50 < 20 µM), were further
screened against axenic amastigote (human life cycle parasite form)
forms. Among these derivatives, Analogues 7d, 7h, 7n and 7g showed
potent inhibition (EC50 0.9, 2.2 3.5 and 3.8 µM respectively) of axenic
amastigotes. Especially, compound 7d exhibited two to three times
more potent anti-amastigote activity than pentamidine and miltefosine
(EC50 1.6 and 2.8 µM). Compounds 7c, 7b, 7f, 7j, 7k and 7a exhibited
significant inhibition (EC50 5.3, 5.8, 6.4, 7.5, 9.3 and 10.0 µM
respectively) of L. donovani axenic amastigotes. Compounds 7p, 7o
and 7i displayed moderate anti-amastigote activity (EC50 12.3, 13.9
and 19.4 µM respectively). Axenic amastigote assay results revealed
that these β-carboline derivatives exhibited potent inhibition of axenic
amastigotes of L. donovani.
2.2.2.2.3. Intracellular amastigote screening. Although, axenic
amastigotes assay most commonly used to screen new leishmanial
agents are different from intracellular amastigotes in terms of protein
expression and drug susceptibility. Hence in our present study,
compounds displayed potent inhibition of promastigote and axenic
amastigotes were further evaluated against intracellular amastigotes to
ensure their activity against clinical relevant forms of parasite.
Intracellular amastigote assay results suggested that, most of these
analogues displayed potent inhibition of L. donovanimacrophagic
amastigotesand the potency was comparable with miltefosine and
many folds higher than pentamidine (Table 2). Especially, compound
7d ((4-(4-methoxyphenyl)piperazin-1-yl)(9-methyl-1-phenyl-9H-pyrido
[3,4-b]indol-3-yl)methan-one) exhibited five times potent inhibition
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(EC50 1.3 µM) of intracellular amastigotes compared to miltefosine
(EC50 6.4 µM). Compounds 7n and 7g were displayed potent anti-
amastigote activity (EC50 5.6 and 6.3 µM) than standard drugs
miltefosine and pentamidine with better selectivity index. Anti-
amastigote potency of 7b, 7c, 7h, 7o and 7p (EC50 7.2, 7.8, 7.9, 7.9
and 9.4 µM) is comparable with miltefosine and better than
pentamidine. Compounds 7k, 7f, 7a, 7j and 7i exhibited good anti-
amastigote activity (EC50 10.1, 11.8, 13.5, 15.4 and 22.0 µM) with
better selectivity.
Structure Activity Relationship (SAR). Structure activity relationship
study suggests that, substitution or replacement of phenyl ring has
significant effect on anti-leishmanial activity as well as cytotoxicity of
these analogues. Among these analogues, un-substituted phenyl deri-
vative displayed significant inhibition of promastigotes, axenic amas-
tigote and intracellular amastigotes of L. donovani. Ortho-para directing
methyl group substitution on ortho and para position enhanced the
potency against axenic amastigotes and intracellular amastigotes of L.
donovani significantly, while on para substitution anti-promastigote
activity altered marginally. Methoxy, chloro group substitution had
strong impact on anti-leishmanial activity of these analogues, position
of substitution is vital in their inhibition activity. Ortho substitution of
methoxy group showed excellent increase in inhibition potency against
promastigotes and both amastigote forms of L. donovani. While methoxy
substitution on ortho position slightly increased the anti-leishmanial
activity, meta substitution resulted in drastic decline in activity. Chloro
substitution on para and meta position has significantly increased the
inhibition potency against tested forms, while on ortho substitution has
marginally affected the activity. Meta directing nitro and fluoro sub-
stitution on para position haven’t showed any considerable effect on
inhibition potency of these analogues. However, fluoro substitution on
ortho position and chloro di-substitution (ortho and meta) significantly
decreased the anti-leishmanial potency. Replacement of phenyl ring
with benzyl ring has significantly enhanced the activity. Even though
pyridyl replacement resulted in increased anti-leishmanial activity, it
also enhanced the cytotoxicity of these analogues. SAR studies sug-
gested that, ortho-para directing methoxy group on para position,
chloro group on para and meta position and benzyl replacement was
recommended for anti-leishmanial activity of these analogues against L.
donovani.
Through the present study, we have identified new lead molecules
with potent anti-leishmaninal activity against L. infantumand L. dono-
vani. Structure activity relationship studies would be utilised to opti-
mize the lead molecules to generate clinically effective against both
drug sensitive and resistance strains of L. infantumand L. donovani.
Table 1
Anti-leishmanial activity of the titled compounds against L. infantum.
Comp. Code R CC50 (µM) L. infantum promastigote EC50 (µM) S.Ia L. infantum Axenic amastigote EC50 (µM) S.Ia
7a –C6H5 > 500 9.45 ± 0.82 > 52.9 4.5 ± 0.3 >111.1
7b –4CH3C6H4 > 500 24.3 ± 1.3 > 20.5 ND –
7c –2CH3C6H4 > 500 3.73 ± 0.28 > 134.0 2.6 ± 0.2 >192.3
7d –4OCH3C6H4 > 500 1.59 ± 0.11 > 314.5 1.4 ± 0.1 >357.1
7e –3OCH3C6H4 > 500 72.4 ± 6.7 > 6.9 ND –
7f –2OCH3C6H4 > 500 13.8 ± 0.9 > 36.2 15.3 ± 1.1 >32.7
7g –4ClC6H4 > 500 1.47 ± 0.32 > 340.1 1.9 ± 0.2 >263.2
7h –3ClC6H4 > 500 50.9 ± 4.8 > 9.8 ND –
7i –2ClC6H4 > 500 21.7 ± 0.6 > 23.0 ND –
7j –4NO2C6H4 > 500 19.7 ± 1.7 > 25.3 14.6 ± 2.9 >34.2
7k –4FC6H4 > 500 17.2 ± 0.82 > 29.1 15.0 ± 1.3 >33.3
7l –2FC6H4 > 500 64.9 ± 5.7 > 7.7 ND –
7m –2,3-diClC6H5 > 500 93.0 ± 7.5 > 5.3 ND –
7n –CH2C6H5 > 500 20.4 ± 1.4 > 24.5 ND –
7o –4C5H4N 29.7 ± 1.5 61.1 ± 5.4 0.48 ND –
7p –2C5H4N 273 ± 21.6 45.7 ± 3.3 5.97 ND –
Pentamidine 8.31 ± 0.18 2.7 ± 0.4
Miltefosine 12.6 ± 1.1 4.8 ± 0.8
a SI=CC50/IC50, ND – Not Determined.
Table 2
Anti-leishmanial activity of the titled compounds against L. donovani.
Compound Code CC50 (µM) L. donovani Promastigote
EC50 (µM)
S.Ia L. donovani Axenic amastigote
EC50 (µM)
S.Ia L. donovani intracellular amastigote
EC50 (µM)
S.Ia
7a >500 11.9 ± 1.2 >42.0 10.0 ± 0.3 50.0 13.5 ± 2.0 37.0
7b >500 14.2 ± 1.2 >35.2 5.8 ± 0.3 86.2 7.9 ± 0.4 63.3
7c >500 9.45 ± 0.72 >52.9 5.3 ± 0.4 94.3 9.4 ± 1.3 53.2
7d >500 0.91 ± 0.09 >549.5 0.9 ± 0.1 555.6 1.3 ± 0.1 384.6
7e >500 28.5 ± 1.8 >17.5 ND – ND –
7f >500 8.42 ± 0.45 >59.4 6.4 ± 0.2 78.1 11.8 ± 0.7 42.4
7g >500 5.02 ± 0.36 >99.6 3.8 ± 0.5 131.6 6.3 ± 0.3 79.4
7h >500 4.0 ± 0.25 >125 2.2 ± 0.1 227.3 7.8 ± 1.3 64.1
7i >500 15.2 ± 0.85 >32.9 19.4 ± 1.2 25.8 22.0 ± 2.1 22.7
7j >500 13.1 ± 1.5 >38.2 7.5 ± 0.4 66.7 15.4 ± 0.9 32.5
7k >500 12.4 ± 1.4 >40.3 9.3 ± 0.5 53.8 10.1 ± 1.1 49.5
7l >500 85.9 ± 7.3 >5.8 ND – ND –
7m >500 117.5 ± 6.4 >4.3 ND – ND –
7n >500 4.57 ± 0.24 >109.4 3.5 ± 0.2 142.9 5.6 ± 0.9 89.3
7o 29.7 ± 1.5 19.5 ± 2.8 1.52 13.9 ± 0.4 2.1 7.2 ± 0.5 4.1
7p 273 ± 21.6 8.5 ± 0.75 45.73 12.3 ± 0.6 22.2 7.9 ± 0.3 34.6
Pentamidine 6.40 ± 0.11 1.6 ± 0.1 23.7 ± 1.8
Miltefosine 3.12 ± 0.16 2.8 ± 0.4 6.4 ± 0.3
a SI=CC50/IC50, ND – Not Determined.
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Exact mechanism of action of these molecules for thier potential ac-
tivity is needs to be evaluated. We hypothesize based upon literature
reports, that these molecules may exhibit the observed potent activity
through interaction with nucleic acids.
3. Conclusion
In summary, we have successfully applied molecular hybridization
technique to design piperazinyl-β-carboline-3-carboxamide derivatives
as anti-leishmanial agents. Designed molecules were synthesized and
evaluated for anti-leishmanial activity against L. infantum and L. do-
novani. Analogues displayed significant inhibition of promastigote
forms (EC50 < 20 μM) were further evaluated against amastigote forms
of respective species. Most of these reported analogues displayed potent
anti-leishmanial activity (promastigote and amastigote forms) against
the both tested strains with better selectivity index. Compounds such
as, 7d, 7g and 7cwereexhibited potent inhibition of promastigote (EC50
1.59, 1.47 and 3.73 µM respectively) and amastigote (EC50 1.4, 1.9 and
2.6 µM respectively) of L. infantum than standard drugs miltefosine,
pentamidine. SAR studied suggested that, ortho-para directing
methoxy, chloro groups substitution on para position as well as methyl
group on ortho position favored the anti-leishmanial activity against L.
infantum.
More interestingly, most of these compounds showed potent anti-
leishmanial activity against L. donovani. Especially, compound 7d dis-
played potent inhibition of L. donovani promastigotes, axenic amasti-
gotes and intracellular amastigotes with EC50 0.91, 0.9 and 1.3 µM re-
spectively. Analogues 7n, 7g and 7h were exhibited potent inhibition
activity against all tested forms of L. donovani. SAR studies suggested
that, ortho-para directing methoxy group on para position, chloro
group on para and meta position were recommended for anti-leish-
manial activity against L. donovani. Although, pyridyl replacement has
increased the inhibition activity as well cytotoxicity and benzyl re-
placement has enhanced the anti-leishmanial activity with better se-
lectivity.
4. Experimental protocols
4.1. Chemistry
All solvents and reagents purchased from Sigma or Merck companies
are used as received without further purification. Solvent system used
throughout the experimental work for running Thin Layer
Chromatography (TLC) was ethyl acetate and hexane mixture (6:4) in
order to monitor the reaction. Column chromatography was performed
using silica gel (100–200 mesh, SRL, India) as stationary phase and
mixture of ethyl acetate and hexane as mobile phase. Melting points are
uncorrected and were determined in open capillary tubes on a Precision
Buchi B530 (Flawil, Switzerland) melting point apparatus containing
silicon oil. IR spectra of the synthesized compounds were recorded using
FT-IR spectrophotometer (Shimadzu IR Prestige 21, India). 1H NMR
spectra were recorded on a Bruker DPX-400 spectrometer (Bruker India
Scientific Pvt. Ltd., Mumbai) using TMS as an internal standard (che-
mical shifts in d, ppm). Elemental analysis was performed on Vario EL III
M/s Elementar C, H, N and S analyzer (ElementarAnalysensysteme
GmbH, Germany). The ESMS were recorded on MICROMASS Quattro-II
LCMS system (Waters Corporation, Milford, USA).
4.2. General procedure for the preparation of 7
To a stirred solution of (6) (0.29 g, 0.001mol) in dry THF, HOBt
(0.16 g, 0.012mol) and EDCI HCl (0.23 g, 0.012mol) were added and
continued stirring for 30min. To the reaction mixture, substituted
phenylpiperazine (0.001mol) was added under ice cold temperature
and the reaction mixture was further stirred at room temperature for
6 h. After completion of reaction as monitored by TLC, solvent was
evaporated under vacuum. Reaction mixture was extracted with ethyl
acetate (2× 20mL), collected organic layer was dried over Na2SO4 and
concentrated under vacuum to get (7a-p).
4.2.1. (9-methyl-1-phenyl-9H-pyrido[3,4-b]indol-3-yl)(4-phenylpiperazin-
1-yl)methanone (7a)
White solid; Yield 76%; mp 232–234 °C; Rf 0.45
(Hexane:EtOAc=6:4); IR νmax/cm−1 (KBr): 3043, 1636, 1564, 1468;
1H NMR (400MHz, CDCl3): δ 8.54 (s, 1H), 8.21 (d, J=7.8 Hz, 1H),
7.70–7.61 (m, 3H), 7.58–7.44 (m, 4H), 7.36 (t, J=7.2 Hz, 1H),
7.30–7.28 (m, 2H), 6.96–6.90 (m, 3H), 4.04 (brs, 4H), 3.52 (s, 3H),
3.33–3.23 (m, 4H); ESI-MS: m/z 447 ((M+1), 100%); Anal. Calcd for
C29H26N4O: C, 78.00; H, 5.87; N, 12.55, Found: C, 78.02; H, 5.85; N,
12.51.
4.2.2. (9-methyl-1-phenyl-9H-pyrido[3,4-b]indol-3-yl)(4-p-tolylpiperazin-
1-yl)methanone (7b)
White solid; Yield 72%; mp 188–190 °C; Rf 0.40
(Hexane:EtOAc=6:4); IR νmax/cm−1 (KBr): 3059, 1652, 1558, 1448;
1H NMR (400MHz, CDCl3): δ 8.55 (s, 1H), 8.23 (d, J=7.8 Hz, 1H),
7.68–7.64 (m, 3H), 7.58–7.53 (m, 3H), 7.48 (d, J=8.3 Hz, 1H), 7.38 (t,
J=7.5 Hz, 1H), 7.11 (d, J=8.2 Hz, 2H), 6.88 (d, J=8.5 Hz, 2H),
4.06–4.04 (m, 4H), 3.54 (s, 3H), 3.29–3.18 (m, 4H), 2.30 (s, 3H); ESI-
MS m/z 461 ((M+1), 100%); Anal. Calcd for C30H28N4O: C, 78.23; H,
6.13; N, 12.16, Found: C, 78.22; H, 6.16; N, 12.14.
4.2.3. (9-methyl-1-phenyl-9H-pyrido[3,4-b]indol-3-yl)(4-o-tolylpiperazin-
1-yl)methanone (7c)
White solid; Yield 64%; mp 148–150 °C; Rf 0.43
(Hexane:EtOAc=6:4); IR νmax/cm−1 (KBr): 3053, 1636, 1552, 1419;
1H NMR (400MHz, CDCl3): δ 8.51 (s, 1H), 8.21 (d, J=7.7 Hz, 1H),
7.65–7.62 (m, 3H), 7.55–7.50 (m, 3H), 7.45 (d, J=8.2 Hz, 1H), 7.36 (t,
J=7.5 Hz, 1H), 7.20–7.15 (m, 2H), 7.01–6.99 (m, 2H), 4.02–4.00 (m,
4H), 3.51 (s, 3H), 3.06–2.94 (m, 4H), 2.35 (s, 3H); ESI-MS m/z 461
((M+1), 100%); Anal. Calcd for C30H28N4O: C, 78.23; H, 6.13; N,
12.16, Found: C, 78.20; H, 6.12; N, 12.18.
4.2.4. (4-(4-methoxyphenyl)piperazin-1-yl)(9-methyl-1-phenyl-9H-pyrido
[3,4-b]indol-3-yl)methanone (7d)
White solid; Yield 82%; mp 170–172 °C; Rf 0.30
(Hexane:EtOAc=6:4); IR νmax/cm−1 (KBr): 3064, 1651, 1516, 1454,
1255; 1H NMR (400MHz, CDCl3): δ 8.53 (s, 1H), 8.21 (d, J=7.8 Hz,
1H), 7.66–7.62 (m, 4H), 7.54–7.50 (m, 4H), 7.45 (d, J=8.3 Hz, 1H),
7.36 (t, J=7.5 Hz, 1H), 6.86 (d, J=8.8 Hz, 2H), 4.10 (brs, 4H), 3.77
(s, 3H), 3.51 (s, 3H), 3.25–3.17(m, 4H); ESI-MS m/z 477 ((M+1),
100%); Anal. Calcd for C30H28N4O2: C, 75.61; H, 5.92; N, 11.76, Found:
C, 75.65; H, 5.88; N, 11.71.
4.2.5. 4.2.6.(4-(3-methoxyphenyl)piperazin-1-yl)(9-methyl-1-phenyl-9H-
pyrido[3,4-b]indol-3-yl)methanone (7e)
White solid; Yield 74%; mp 196–198 °C; Rf 0.35
(Hexane:EtOAc=6:4); IR νmax/cm−1 (KBr): 3057, 1625, 1556, 1454,
1435, 1253; 1H NMR (400MHz, CDCl3): δ 8.54 (s, 1H), 8.21 (d,
J=7.8 Hz, 1H), 7.66–7.62 (m, 3H), 7.56–7.50 (m, 3H), 7.46 (d,
J=8.3 Hz, 1H), 7.36 (t, J=7.5 Hz, 1H), 7.20 (t, J=8.0 Hz, 1H),
6.62–6.48 (m, 3H), 4.13–4.07 (m, 4H), 3.80 (s, 3H), 3.52 (s, 3H),
3.36–3.26 (m, 4H); ESI-MS m/z 477 ((M+1), 100%); Anal. Calcd for
C30H28N4O2: C, 75.61; H, 5.92; N, 11.76, Found: C, 75.58; H, 5.94; N,
11.79.
4.2.6. (4-(2-methoxyphenyl)piperazin-1-yl)(9-methyl-1-phenyl-9H-pyrido
[3,4-b]indol-3-yl)methanone (7f)
White solid; Yield 62%; mp 168–170 °C; Rf 0.35
(Hexane:EtOAc=6:4); IR νmax/cm−1 (KBr): 3053, 1643, 1556, 1496,
1240; 1H NMR (400MHz, CDCl3): δ 8.54 (s, 1H), 8.23 (d, J=7.8 Hz,
1H), 7.68–7.64 (m, 3H), 7.58–7.52 (m, 3H), 7.48 (d, J=8.3 Hz, 1H),
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7.38 (t, J=7.5 Hz, 1H), 7.06–7.04 (m, 1H), 6.96–6.90 (m, 3H), 4.08
(brs, 4H), 3.90 (s, 3H), 3.54 (s, 3H), 3.22–3.12 (m, 4H); ESI-MS m/z 477
((M+1), 100%); Anal. Calcd for C30H28N4O2: C, 75.61; H, 5.92; N,
11.76, Found: C, 75.63; H, 5.97; N, 11.73.
4.2.7. (4-(4-chlorophenyl)piperazin-1-yl)(9-methyl-1-phenyl-9H-pyrido
[3,4-b]indol-3-yl)methanone (7g)
White solid; Yield 76%; mp 160–162 °C; Rf 0.40
(Hexane:EtOAc= 6:4); IR νmax/cm−1 (KBr): 3055, 1633, 1556, 1471,
756; 1H NMR (400MHz, CDCl3): δ 8.57 (s, 1H), 8.24 (d, J=7.8 Hz,
1H), 7.68–7.64 (m, 3H), 7.56–7.53 (m, 3H), 7.50–7.48 (m, 1H),
7.41–7.37 (m, 1H), 7.26 (d, J=8.9 Hz, 2H), 7.02–6.95 (m, 2H), 4.10
(brs, 4H), 3.54 (s, 3H), 3.34–3.25 (m, 4H); ESI-MS m/z 481 ((M+1),
100%), 483 ((M+3), 33%); Anal. Calcd for C29H25ClN4O: C, 72.42; H,
5.24; N, 11.65, Found: C, 72.39; H, 5.26; N, 11.63.
4.2.8. (4-(3-chlorophenyl)piperazin-1-yl)(9-methyl-1-phenyl-9H-pyrido
[3,4-b]indol-3-yl)methanone (7h)
White solid; Yield 70%; mp 130–132 °C; Rf 0.42
(Hexane:EtOAc= 6:4); IR νmax/cm−1 (KBr): 3069, 1614, 1556, 1487,
736; 1H NMR (400MHz, CDCl3): δ 8.52 (s, 1H), 8.19 (d, J=7.9 Hz,
1H), 8.01–7.99 (m, 2H), 7.66–7.53 (m, 5H), 7.39–7.35 (m, 1H), 7.21 (t,
J=8.1 Hz, 1H), 6.93 (t, J=2.1 Hz, 1H), 6.88–6.82 (m, 2H), 4.12–4.06
(m, 4H), 3.54 (s, 3H), 3.38–3.31 (m, 4H); ESI-MS m/z 481 ((M+1),
100%), 483 ((M+3), 33%); Anal. Calcd for C29H25ClN4O: C, 72.42; H,
5.24; N, 11.65, Found: C, 72.46; H, 5.27; N, 11.68.
4.2.9. (4-(2-chlorophenyl)piperazin-1-yl)(9-methyl-1-phenyl-9H-pyrido
[3,4-b]indol-3-yl)methanone (7i)
White solid; Yield 66%; mp 152–154 °C; Rf 0.40
(Hexane:EtOAc= 6:4); IR νmax/cm−1 (KBr): 3043, 1629, 1556, 1435,
734; 1H NMR (400MHz, CDCl3): δ 8.51 (s, 1H), 8.21 (d, J=7.8 Hz,
1H), 7.65–7.62 (m, 3H), 7.56–7.44 (m, 4H), 7.46–7.44 (m, 2H),
7.24–7.20 (m, 1H), 7.05–6.97 (m, 2H), 4.04 (brs, 4H), 3.51 (s, 3H),
3.19–3.08 (m, 4H);ESI-MS m/z 481 (((M+1), 100%), 483 ((M+3),
33%); Anal. Calcd for C29H25ClN4O: C, 72.42; H, 5.24; N, 11.65, Found:
C, 72.40; H, 5.20; N, 11.64.
4.2.10. (9-methyl-1-phenyl-9H-pyrido[3,4-b]indol-3-yl)(4-(4-nitrophenyl)
piperazin-1-yl)methanone (7j)
Yellow solid; Yield 70%; mp 200–202 °C; Rf 0.30
(Hexane:EtOAc= 6:4); IR νmax/cm−1 (KBr): 3053, 1633, 1597, 1471,
1303, 754; 1H NMR (400MHz, CDCl3): δ 8.55 (s, 1H), 8.19–8.14 (m,
3H), 7.97 (d, J=7.1 Hz, 2H), 7.64–7.51 (m, 5H), 7.38–7.34 (m, 1H),
6.84 (d, J=9.4 Hz, 2H), 4.19–4.06 (m, 4H), 3.51 (s, 3H), 3.64–3.56
(m, 4H);ESI-MS m/z 492 ((M+1),100%); Anal. Calcd for C29H25N5O3:
C, 70.86; H, 5.13; N, 14.25, Found: C, 70.82; H, 5.12; N, 14.28.
4.2.11. (4-(4-fluorophenyl)piperazin-1-yl)(9-methyl-1-phenyl-9H-pyrido
[3,4-b]indol-3-yl)methanone (7k)
White solid; Yield 76%; mp 188–190 °C; Rf 0.40
(Hexane:EtOAc=6:4); IR νmax/cm−1 (KBr): 3057, 1614, 1556, 1487,
736; 1H NMR (400MHz, CDCl3): δ 8.56 (s, 1H), 8.23 (d, J=7.7Hz, 1H),
7.68–7.65 (m, 3H), 7.58–7.53 (m, 3H), 7.48 (d, J=8.4Hz, 1H), 7.38 (td,
J=7.6, 0.8 Hz, 1H), 7.06–6.96 (m, 2H), 6.96–6.88 (m, 2H), 4.06–4.05
(m, 4H), 3.54 (s, 3H), 3.26–3.16 (m, 4H);ESI-MS m/z 465
((M+1),100%); Anal. Calcd for C29H25FN4O: C, 74.98; H, 5.42; N,
12.06, Found: C, 74.94; H, 5.45; N, 12.03.
4.2.12. (4-(2-fluorophenyl)piperazin-1-yl)(9-methyl-1-phenyl-9H-pyrido
[3,4-b]indol-3-yl)methanone (7l)
White solid; Yield 68%; mp 168–170 °C; Rf 0.45
(Hexane:EtOAc= 6:4); IR νmax/cm−1 (KBr): 3055, 1633, 1556, 1471,
1435, 756; 1H NMR (400MHz, CDCl3): δ 8.53 (s, 1H), 8.21 (d,
J=7.8 Hz, 1H), 7.65–7.62 (m, 3H), 7.55–7.50 (m, 3H), 7.45 (d,
J=8.3 Hz, 1H), 7.36 (t, J=7.5 Hz, 1H), 7.07–6.93 (m, 4H), 4.05–4.04
(m, 4H), 3.51 (s, 3H), 3.23–3.13 (m, 4H); ESI-MS m/z 465
((M+1),100%); Anal. Calcd for C29H25FN4O: C, 74.98; H, 5.42; N,
12.06, Found: C, 74.96; H, 5.39; N, 12.10.
4.2.13. (4-(2,3-dichlorophenyl)piperazin-1-yl)(9-methyl-1-phenyl-9H-
pyrido[3,4-b]indol-3-yl)methanone (7m)
White solid; Yield 74%; mp 166–168 °C; Rf 0.32
(Hexane:EtOAc=6:4); IR νmax/cm−1 (KBr): 3059, 1614, 1556, 1438,
790, 736; 1H NMR (400MHz, CDCl3): δ 8.52 (s, 1H), 8.21 (d,
J=7.8 Hz, 1H), 7.67–7.62 (m, 3H), 7.58–7.48 (m, 3H), 7.46 (d,
J=8.3 Hz, 1H), 7.36 (t, J=7.5 Hz, 1H), 7.20–7.11 (m, 2H), 6.95 (dd,
J=7.6, 1.9 Hz, 1H), 4.04 (brs, 4H), 3.51 (s, 3H), 3.18–3.08 (m, 4H);
ESI-MS m/z 516 (((M+1), 100%), 518 ((M+3), 66%), 518 ((M+5),
10%)); Anal. Calcd for C29H24Cl2N4O: C, 67.58; H, 4.69; N, 10.87,
Found: C,67.62; H, 4.64; N, 10.91.
4.2.14. (4-benzylpiperazin-1-yl)(9-methyl-1-phenyl-9H-pyrido[3,4-b]
indol-3-yl)methanone (7n)
White solid; Yield 78%; mp 158–160 °C; Rf 0.40
(Hexane:EtOAc=6:4); IR νmax/cm−1 (KBr): 3055, 1614, 1552, 1438,
1409; 1H NMR (400MHz, CDCl3): δ 8.50 (s, 1H), 8.22 (d, J=7.7 Hz,
1H), 7.66–7.62 (m, 3H), 7.56–7.52 (m, 3H), 7.47 (d, J=8.3 Hz, 1H),
7.39–7.34 (m, 5H), 7.30–7.28 (m, 1H), 3.91–3.87 (m, 4H), 3.57 (s, 2H),
3.52 (s, 3H), 2.62–2.48 (m, 4H); ESI-MS m/z 461 ((M+1), 100%);
Anal. Calcd for C30H28N4O: C, 78.23; H, 6.13; N, 12.16, Found: C,
78.26; H, 6.11; N, 12.19.
4.2.15. (9-methyl-1-phenyl-9H-pyrido[3,4-b]indol-3-yl)(4-(pyridin-4-yl)
piperazin-1-yl)methanone (7o)
Yellowish white solid; Yield 68%; mp 198–200 °C; Rf 0.35
(Hexane:EtOAc=2:8); IR νmax/cm−1 (KBr): 3053, 1620, 1558, 1456;
1H NMR (400MHz, CDCl3): δ 8.59 (s, 1H), 8.31 (d, J=5.4 Hz, 2H),
8.24 (d, J=7.8 Hz, 1H), 7.68–7.62 (m, 3H), 7.58–7.55 (m, 3H), 7.50
(d, J=8.4 Hz, 1H), 7.38 (t, J=7.5 Hz, 1H), 6.68 (d, J=6.0 Hz, 2H),
4.10–4.03 (m, 4H), 3.51 (s, 3H), 3.53–3.42 (m, 4H);ESI-MS m/z 448
((M+1), 100%); Anal. Calcd for C28H25N5O: C, 75.15; H, 5.63; N,
15.65, Found: C, 75.19; H, 5.68; N, 15.68.
4.2.16. (9-methyl-1-phenyl-9H-pyrido[3,4-b]indol-3-yl)(4-(pyridin-2-yl)
piperazin-1-yl)methanone (7p)
Yellowish white solid; Yield 62%; mp 174–176 °C; Rf 0.30
(Hexane:EtOAc=2:8); IR νmax/cm−1 (KBr): 3053, 1614, 1556, 1487,
1471; 1H NMR (400MHz, CDCl3): δ 8.57 (s, 1H), 8.24–8.21 (m, 2H),
7.69–7.65 (m, 3H), 7.58–7.47 (m, 5H), 7.38 (t, J=7.5 Hz, 1H),
6.69–6.66 (m, 2H), 4.02 (brs, 4H), 3.71–3.69 (m, 4H), 3.55 (s, 3H); ESI-
MS m/z 448 ((M+1), 100%); Anal. Calcd for C28H25N5O: C, 75.15; H,
5.63; N, 15.65, Found: C, 75.12; H, 5.61; N, 15.62.
4.3. Biological evaluation
4.3.1. Cytotoxicity assay
HeLa cell cytotoxicity studies were carried out as described pre-
viously. Briefly, the cells were cultured in DMEM supplemented with
10% fetal calf serum and 2mM L-glutamine. Cells were plated at initial
cell concentration of 2×104 cells/well and incubated with the com-
pounds for ∼65 h prior to addition of Alamar Blue solution for further
5 h [36].
4.3.2. Promastigote assay
L. donovanipromastigotes were cultured at 37 °C in M199 medium
supplemented with 10% heat-inactivated fetal calf serum. L. infantum
JPCM5 MCAN/ES/98/LLM-87 promastigotes were cultured at 26 °C in
modified Eagle’s medium (HOMEM) [37]. Parasites were incubated
with serial dilutions of compounds for 72 h, followed by Alamar blue-
based assay as previously described [38].
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4.3.3. Axenic amastigote assay
L. donovaniLdBOB axenic amastigotes or L. infantum JPCM5 MCAN/
ES/98/LLM-87 were cultured at 37 °C in modified Eagle’s medium
(HOMEM; L. infantum) and axenic amastigotes were incubated for 72 h
with compounds, followed by Alamar blue-based assay as previously
described [38].
4.3.4. Intra macrophage L. donovani (amastigote) assay
THP-1 (human monocytic leukemia) cells were a kind gift from Dr
Susan Wylie (Dundee) and maintained in minimal essential medium
plus 10% (vol/vol) FBS. An intracellular Leishmania assay using LdBOB
amastigotes were performed utilizing PMA differentiated THP-1 cells
infected overnight with axenic amastigotes, prior to compounds being
added and incubated for further 72 h, subsequent microscopy-based
readout was used to determine EC50 values [38]. Briefly, THP-1 cells
(20,000 per well, 200 µL) were plated into 96 well plates in presence of
10 nM PMA and incubated at 37 °C in 5% CO2 atmosphere for 75 h. The
adhered cells were then washed with phosphate buffered saline sup-
plemented with 1mM CaCl2, 0.5 mM MgCl2, 0.1% (w/v) bovine serum
albumin and using LdBOB amastigotes added to all wells at a multi-
plicity of infection of 5 (100,000 amastigotes per well) and incubated
for 18 h. Any remaining extracellular amastigotes were removed and
the adhered cells were washed with the same supplemented PBS solu-
tion as above. Pre-aliquoted compounds in a serial dilution were added
from another plate, such that the total well volume was 200 μL and
incubated for further 72 h. Cells were fixed with 100% methanol,
stained with Giemsa and examined microscopically. Number of in-
tracellular amastigotes (∼200 macrophages per well) were determined
and the percentage infection was established compared to an untreated
control (100%) allowing EC50 values to be calculated [38].
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